2021
SARS-CoV-2 in Nursing Homes after 3 Months of Serial, Facilitywide Point Prevalence Testing, Connecticut, USA - Volume 27, Number 5—May 2021 - Emerging Infectious Diseases journal - CDC
Ehrlich HY, Harizaj A, Campbell L, Colt M, Yuan K, Rabatsky-Ehr T, Weinberger DM, Leung V, Niccolai LM, Parikh S. SARS-CoV-2 in Nursing Homes after 3 Months of Serial, Facilitywide Point Prevalence Testing, Connecticut, USA - Volume 27, Number 5—May 2021 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2021, 27: 1288-1295. PMID: 33900171, PMCID: PMC8084507, DOI: 10.3201/eid2705.204936.Peer-Reviewed Original ResearchConceptsPoint prevalence surveyNursing homesInfectious Diseases journal - CDCPublic health surveillance dataInfection prevention measuresNursing home staffSARS-CoV-2Health surveillance dataPoisson regression modelsCommunity incidenceIncidence ratePrevalence surveyHome staffInfectious personsCoronavirus diseaseInfection statusOutbreak controlSurveillance dataPrevention measuresIncidenceRegression modelsDisease spreadStaffHomeResidents
2020
Molecular surveillance of antimalarial partner drug resistance in sub-Saharan Africa: a spatial-temporal evidence mapping study
Ehrlich HY, Jones J, Parikh S. Molecular surveillance of antimalarial partner drug resistance in sub-Saharan Africa: a spatial-temporal evidence mapping study. The Lancet Microbe 2020, 1: e209-e217. PMID: 33089222, PMCID: PMC7575134, DOI: 10.1016/s2666-5247(20)30094-x.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyPartner drug resistanceDrug resistanceSurveillance dataDrug resistance surveillanceACT partner drugsMalaria-endemic countriesSentinel surveillance systemDrug surveillance dataAntimalarial drug resistanceSaharan AfricaPartner drugsCombination therapyAntimalarial resistanceSurveillance sitesMarker prevalenceResistance surveillanceMedian time lagMolecular surveillanceSystematic searchResistance-associated markersMean amountSub-Saharan countries